Sandoz’ Omnitrope Approved
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA notes that approval of the Genotropin follow-on does not establish a pathway for follow-on protein products regulated under the Public Health Service Act.
You may also be interested in...
FDA Cites Immunogenicity Concerns In “Not Approvable” Letter For Momenta/Sandoz’s Lovenox Generic
Firm is “confident” no immunogenicity differences will arise, Momenta CEO Wheeler says.
FDA Cites Immunogenicity Concerns In “Not Approvable” Letter For Momenta/Sandoz’s Lovenox Generic
Firm is “confident” no immunogenicity differences will arise, Momenta CEO Wheeler says.
Sandoz Will Launch Biosimilar Epoetin Alfa In Europe At Up To 30 Percent Discount To Branded Products
EU approval further demonstrates need for U.S. follow-on pathway, Sandoz VP-Global Head of Biopharma Development Ajaz Hussain tells “The Pink Sheet” DAILY.